NCT07218627

A Research Study on the Effects of NNC0537-1482 in Participants With Heart Failure

A Randomised, Placebo-controlled, Double-blinded Phase 1b Study Investigating Safety, Tolerability, Pharmacokinetics and Effects on Biomarkers From Multiple Ascending Doses of NNC0537-1482 in Participants With Heart Failure

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 36 (estimated)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: 40 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The study is testing a new drug (NNC0537-1482) to potentially treat people with heart failure. The purpose of the study is to see if NNC0537-1482 is safe and how it works in the body. Participants will either get NNC0537-1482 or placebo (a "dummy drug" without any active ingredients) and which treatment they get is decided by chance. This study will last up to 64 days with an additional screening period up to 28 days.

Conditions

• Heart Failure

Interventions

Type	Name	Description
DRUG	NNC0537-1482	NNC0537-1482 will be administered subcutaneously.
DRUG	Placebo	Placebo will be administered subcutaneously.

Timeline

• Start date: 2025-10-23
• Primary completion: 2027-01-15
• Completion: 2027-01-15
• First posted: 2025-10-20
• Last updated: 2025-12-05

Locations

1 site across 1 country: United Kingdom